Aptys Pharma is pleased to welcome Cécile Thébault to its strategic committee.
A graduate of ESC Clermont-Ferrand and holder of a post-graduate degree in strategic marketing, she has been working for over thirty-five years as a private equity/innovation investor, focusing mainly on life sciences and the environment (health, food, agri-food, green chemistry). Following activities in growth capital and strategy consulting, she was responsible for setting up the Capital-Innovation department within the Sofimac group (now UI Investissement) from 1999 to 2000, and she managed investments for several technology funds, with one specializing in medical technologies.
When in charge of a portfolio of young innovative companies, she monitored and steered the funding of several technology companies from their seed stage to their industrial transfer, IPO or Series A, while sitting on the boards of Metabolic Explorer, Cyclopharma Laboratories, Genolife, Opi, Biom’up, Theranexus, Afyren, Invers, Sabi Agri… Currently Investment Director at UI Investissement, Cécile is a strategic asset for the development of APTYS PHARMA. All members of the APTYS team welcome Cécile Thébault.